Advances in biology and management of bladder cancerNew Therapeutic Challenges in Advanced Bladder Cancer
Section snippets
First-Line Chemotherapy
Even though urothelial carcinoma is an aggressive epithelial tumor compared with other solid tumors, it is rather sensitive to chemotherapy. Therefore, chemotherapy with a regimen to which the patient has been unexposed remains the treatment of choice for patients with advanced bladder cancer. Different cytotoxic drugs with antitumor activity in metastatic urothelial carcinoma have shown responses in a domain of potential clinical utility (Table 1), ranging from single-agent response rates of
Summary/Conclusions
Treatment of advanced bladder cancer continues to be challenging in both the first- and second-line settings and in fit and unfit patients. Limited advances have been made with chemotherapy, including the design of the triplet regimen and the incorporation of dose-intensification (dose-dense) formulations. In second-line, vinflunine has recently been approved as monotherapy based on a superior benefit in overall survival in the population of patients that were fully eligible to be included in
References (62)
- et al.
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world
J Urol
(1995) - et al.
Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents
Crit Rev Oncol Hematol
(2009) - et al.
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
Eur J Cancer
(2006) - et al.
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinumItalian Co-operative Group on Bladder Cancer
Eur J Cancer
(1998) - et al.
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol
(2011) - et al.
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
Lancet Oncol
(2011) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine
Eur J Cancer
(2012) - et al.
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]
Ann Oncol
(2011) - et al.
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulinDiscovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data
J Biol Chem
(1991)
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder
Ann Oncol
Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response
Cancer Lett
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
Ann Oncol
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy
Neoplasia
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study
J Clin Oncol
Methotrexate: an active drug in bladder cancer
Cancer
Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group
J Clin Oncol
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients
Br J Cancer
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
J Clin Oncol
Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tractA Northern California Oncology Group study
J Clin Oncol
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urotheliumEfficacy and patterns of response and relapse
Cancer
NCCN clinical practice guidelines in oncology; bladder cancer
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
J Clin Oncol
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
J Clin Oncol
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924
J Clin Oncol
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group
J Clin Oncol
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium
Cancer
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer
J Clin Oncol
Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial
Ann Oncol
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group
J Clin Oncol
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
J Clin Oncol
Cited by (98)
Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma
2023, International ImmunopharmacologyEstablishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response
2024, Bioengineering and Translational MedicineSarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy
2024, International Journal of Clinical OncologyPrediction of Ki-67 expression in bladder cancer based on CT radiomics nomogram
2024, Frontiers in Oncology
Conflicts of interest: J.B.—consultancy and lectures fee from Pierre Fabre; D.P.P.—research support from Lilly Oncology, Sanofi Aventis.